Skip to content

Scaffold in Emilia Romagna and in the MAGIC Network

Scaffold Implantation in Emilia-Romagna Plus Multi Absorbable Gears Intra Coronary

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03327961
Acronym
SHERPA-MAGIC
Enrollment
1111
Registered
2017-11-01
Start date
2017-12-02
Completion date
2034-12-31
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The prospective study will investigate the clinical performance and long-term safety of scaffold implantation in a real world regional setting. The protocol includes two different networks. The first network includes all cath-labs in the Emilia-Romagna region (SHERPA). The second includes the centers partecipating into the MAGIC retrospective study. Both networks joined into the prospective SHERPA-MAGIC project. Investigators from both networks agreed in indications and strategy implanatation described by the protocol. In each center, after IRB approval, the patients will be enrolled according to established criteria.

Detailed description

Coronary stents are the default devices for the treatment of coronary artery disease in percutaneous coronary intervention (PCI) according to existing guidelines. However, thrombosis and restenosis are still the main limitations of current permanent metallic stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced restenosis rate due to the presence of antiproliferative agents in the coating layer of the stent surface and reduced rate of repeat revascularisation. However, late and very late stent thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet therapy. Bioabsorbable scaffolds have been introduced to overcome limitations of permanent metallic stents. The aim of this observational prospective study is to investigate the clinical performance and long-term safety of scaffold in a real world regional setting. The investigators agreed in the following preferential/optimal indications: * complete revascularization in patients with age \<65 years * revascularization of long lesions (\>24 mm), especially located in left anterior descending * spontaneous coronary dissection The investigators agreed in the following strategy implantation: * mandatory predilatation * sizing 1:1 * to avoid vessel with reference vessel diameter \<2.8 mm and \>3.8 mm * to avoid vessel with severe calcifications * mandatory postdilation with non compliant balloon ≥0.5 the scaffold diameter The study organization is based on: DATA SAFETY MONITORING BOARD (DSMB) All adverse events will be reported to the DSMB and reviewed on an on-going basis throughout the subject enrolment and follow-up period to ensure the safety of subjects enrolled in this study. The DSMB may request additional information as needed. CORE LABORATORY ANALYSIS All coronary artery angiographies and percutaneous coronary interventions will be reviewed by an indipendent core-lab. The core-lab will perform quantitative coronary analysis and assessment of the agreement between implantation technique in each case and established criteria

Interventions

DEVICEscaffold

implantation of scaffold (eg Magmaris, Desolve, Others)

Sponsors

University Hospital of Ferrara
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* subjects \>18 years * sign of the patients informed consent * implanation of at least one scaffold

Exclusion criteria

* inability to garantuee at least one year follow-up * inabiliuty to garantuee at least one year compliance to dual antiplatelet regimen

Design outcomes

Primary

MeasureTime frameDescription
Device Oriented Cardiac Events1 yearcumulative occurence of cardiovascular death, target vessel myocardial infarction and target vessel revascularization. Target is defined the vessel treated with scaffold

Countries

Italy

Contacts

Primary ContactVeronica Lodolini
ldlvnc@unife.it0532236450
Backup ContactElisa Mosele
elisa21mosele@gmail.com0532236450

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026